3 High-Yield Healthcare Stocks to Buy With $1,000 and Hold Through Any Market

The article highlights above-market forward dividend yields of 5.7% for Pfizer, 4.1% for Bristol Myers Squibb and 3.0% for Medtronic, versus 1.1% for the S&P 500. Pfizer’s Q3 revenue was flat at $16.6 billion year over year, though revenue excluding coronavirus products rose 7%; Bristol Myers’ Q3 revenue increased 7% to $13.1 billion, and Medtronic’s fiscal Q1 2027 revenue rose 13.7% to $9.8 billion. The author favors Medtronic’s prospects and proposes allocating slightly more than half of a hypothetical $1,000 investment to it, with the remainder split between Pfizer and Bristol Myers.

Analysis

The dividend framing obscures the key distinction: PFE and BMY are both exposed to the same Eliquis patent-cycle risk, so owning both provides less diversification than the three-name allocation implies. Their newer-product growth is encouraging, but it must replace mature-product revenue while preserving cash available for dividends; pipeline counts are not a substitute for launch-level sales and free-cash-flow evidence. Treat both yields as compensation for execution and patent risk, not as evidence of a floor.

MDT has the cleaner near-term operating setup if post-spin results confirm better margins and underlying growth. The counterpoint is that the reported growth rate alone does not establish durable organic momentum, and Hugo must win adoption against established surgical-robotics competitors such as Intuitive Surgical (ISRG). In cardiac ablation, Abbott and Boston Scientific are relevant competitive checks. Any device share gains could therefore be gradual and require commercial investment before they show up in profit.

Over the next 1–3 months, the useful catalysts are company guidance, continuing-business growth and cash conversion at MDT, and product-level growth plus free cash flow at PFE/BMY. Over 6–18 months, the question is whether launches and pipeline approvals offset patent erosion without weakening dividend coverage. The contrarian point: a high yield can persist—or rise—if the market doubts replacement economics; the article’s optimistic framing does not resolve that risk.

Key Decisions for Investors

• Prefer MDT over an equal-weight basket of the three for incremental healthcare exposure, but build only after verifying post-spin organic growth, margins and free-cash-flow conversion. Reassess if continuing-business growth or cash generation deteriorates, or if Hugo adoption fails to develop.
• Do not treat PFE and BMY as independent income diversifiers: both share Eliquis exposure. If holding both, cap combined pharma exposure and monitor Eliquis sales, patent timing, replacement-product revenue and dividend coverage at each earnings report.
• Avoid buying PFE or BMY solely for yield. Require evidence that newer products are replacing mature-product declines in reported revenue and free cash flow; a weaker outlook or declining cash coverage would falsify the income thesis.
• Watch a relative-value long MDT / underweight PFE-BMY setup rather than initiating a short without valuation and borrow analysis. The thesis is improving device fundamentals versus concentrated patent-replacement risk; revisit if MDT’s underlying growth or margins disappoint, or pharma replacement growth accelerates enough to offset erosion.